We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 18.00 | 17.50 | 18.50 | 18.00 | 18.00 | 18.00 | 31,591 | 07:49:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.34 | 16.41M |
From Apr 2019 to Apr 2024
TIDMOPTI
RNS Number : 2597K
OptiBiotix Health PLC
06 July 2017
OptiBiotix Health plc
("OptiBiotix" or the Company")
Grant of Options
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the grant of options to Per Rehné and Christina Wood, both Directors of the Company at an exercise price of 69.5p. Full details of the options agreement for the relevant parties are set out in the table below.
Per Rehné ------------------------------- ---------------- Number of Shares under option 500,000 ------------------------------- ---------------- Exercise Price 69.5p ------------------------------- ---------------- Expiration date 23 June 2027 ------------------------------- ---------------- Interests following grant 500,000 options (shares/options) ------------------------------- ---------------- Christina Wood ------------------------------- ---------------- Number of Shares under option 500,000 ------------------------------- ---------------- Exercise Price 69.5p ------------------------------- ---------------- Expiration date 23 June 2027 ------------------------------- ---------------- Interests following grant 500,000 options (shares/options) ------------------------------- ----------------
Under the terms of the agreement the options are exercisable on meeting commercial targets including cumulative revenues for each area of director's responsibility.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Hot Features
Premium
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
-----------------------------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
----- ----------------------------------------------------------------------
a. Name Per Rehné
----- ------------------------------- -------------------------------------
2 Reason for notification
----- ------------------------------- -------------------------------------
a. Position/Status PDMR
----- ------------------------------- -------------------------------------
b. Initial notification/ Initial Notification
Amendment
----- ------------------------------- -------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
----- ----------------------------------------------------------------------
a. Name OptiBiotix Health Plc
----- ------------------------------- -------------------------------------
b. LEI N/A
----- ------------------------------- -------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
----- ----------------------------------------------------------------------
a. Description of the Options over 500,000 ordinary
financial instrument, shares of 2p each
type of instrument
Identification Code
ISIN: GB00BP0RTP38
----- ------------------------------- -------------------------------------
b. Nature of the transaction Award of option to purchase
ordinary shares of the Company.
Following the transaction,
Mr Per Rehné has an
interest in options 500,000
over ordinary shares.
----- ------------------------------- -------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
----- ------------------------------- ---------------- -----------------
69.5p 500,000
---------------- -----------------
Aggregated information
- Aggregated Volume 500,000
d. - Price 69.5p
----- ------------------------------- -------------------------------------
e. Date of the transaction 29 June 2017
----- ------------------------------- -------------------------------------
f. Place of the transaction London Stock Exchange, AIM
----- ------------------------------- -------------------------------------
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
--------------------------------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
----- -------------------------------------------------------------------------
a. Name Christina Wood
------------------------------------------
2 Reason for
notification
----- ----------------------------- ------------------------------------------
a. Position/Status PDMR
----- ----------------------------- ------------------------------------------
b. Initial notification/ Initial Notification
Amendment
----- ----------------------------- ------------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
-------------------------------------------------------------------------
a. Name OptiBiotix Health Plc
----- ----------------------------- ------------------------------------------
b. LEI N/A
----- ----------------------------- ------------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
----- -------------------------------------------------------------------------
a. Description Options over 500,000 ordinary
of the financial shares of 2p each
instrument,
type of instrument
Identification ISIN: GB00BP0RTP38
Code
----- ----------------------------- ------------------------------------------
b. Nature of the Award of option to purchase ordinary
transaction shares of the Company. Following
the transaction, Mrs Christina
Wood has an interest in options
500,000 over ordinary shares.
----- ----------------------------- ------------------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s)
----- ----------------------------- ------------------- ------------------
69.5p 500,000
------------------- ------------------
Aggregated
information
- Aggregated
Volume 500,000
d. - Price 69.5p
----- ----------------------------- ------------------------------------------
e. Date of the 29 June 2017
transaction
----- ----------------------------- ------------------------------------------
f. Place of the London Stock Exchange, AIM
transaction
----- ----------------------------- ------------------------------------------
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the grant of options to Commercial Director Per Rehne, and Sales and Marketing Director Christina Wood, who are leading the commercialisation of OptiBiotix's products in global markets. Christina is leading the commercialisation of SlimBiome whilst Per is leading the commercialisation of LP(LDL..) The options are exercisable on achieving a number of cumulative revenue milestones for each area of director's responsibility designed to focus both efforts and activity on rapidly growing revenues."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHSSWEFIFWSELW
(END) Dow Jones Newswires
July 06, 2017 02:00 ET (06:00 GMT)
1 Year Optibiotix Health Chart |
1 Month Optibiotix Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
